DRM02, a novel phosphodiesterase-4 inhibitor with cutaneous anti-inflammatory activity
{{output}}
Chronic inflammatory skin disorders are frequently associated with impaired skin barrier function. Selective phosphodiesterase-4 (PDE4) inhibition constitutes an effective therapeutic strategy for the treatment of inflammatory skin diseases. We now report the ... ...
